Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthcare Conference
Fulgent Genetics (NASDAQ: FLGT) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. The company's executives, including Chairman and CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, will host a presentation at 8:40 a.m. ET.
A live webcast of the event will be accessible via the Investor Relations section of Fulgent Genetics' website.
- None.
- None.
TEMPLE CITY, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021. These representatives of the company will host a presentation beginning at 8:40 a.m. ET.
A live webcast of the presentation will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) - based tests. The Company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633; nicole@blueshirtgroup.com
FAQ
What is Fulgent Genetics' participation in the Oppenheimer Healthcare Conference 2021?
Who will represent Fulgent Genetics at the Oppenheimer Conference?
Where can I watch the Fulgent Genetics presentation live?
What technologies does Fulgent Genetics offer?
How has Fulgent Genetics contributed to COVID-19 testing?
